Slide 1: 2022 First Nine Months Results
2022 First Nine Months Results Milano, 08th November 2022
Slide 2: First nine months 2022 key highlights
First nine months 2022 key highlights • Very strong YTD operating performance, with Revenue and EBITDA ahead of expectations • Net Revenue of €1,377.5 million, +19.1% overall, with organic growth at CER(1) of +10.4%: - Continued strong momentum in SPC, ahead of relevant markets, driven by Cough & Co
Slide 3: Key Rare Diseases franchises performance
Key Rare Diseases franchises performance Strong growth of Endo and Oncology franchises, on track with longer term ambitions (million Euro) Endo RRD Revenue Oncology RRD (ex. EUSA Pharma) pro-forma Revenue(1) +40% +13% 126.6 129.5 114.8 90.5 59.8 32.0 91.1 58.5 66.8 38.4 9M 2021 9M 2022 9M 2021 9M 20
Slide 4: Main products sales
Main products sales (million Euro) 9M 2022 9M 2021 Change % Zanidip® and Zanipress® (lercanidipine+enalapril)(1) 131.9 138.5 (4.7) Seloken®/Seloken® ZOK/Logimax® 72.5 73.0 (0.7) (metoprolol/metoprolol+felodipine) Eligard®(2) 78.6 59.4 32.5 Urorec® (silodosin) 46.2 45.3 2.0 Livazo® (pitavastatin) 35.
Slide 5: A diversified product portfolio
A diversified product portfolio Other corporate products 9.9% (excluding OTC) Drugs for rare diseases Livazo® 2.6% 31.2% Zanipress® 2.1% Urorec® 3.4% Eligard® 5.7% Seloken®/Logimax® 5.3% Zanidip® 7.5% OTC 16.4% Pharmaceutical chemicals 2.6% Other revenue 0.4% Subsidiaries’ local product portfolios 1
Slide 6: Composition of revenue by geography
Composition of revenue by geography (million Euro) 9M 2022 9M 2021 Change % Italy 206.8 195.8 5.6 U.S.A. 190.7 127.5 49.6 France 126.2 112.2 12.4 Germany 123.9 111.7 10.9 Spain 104.5 85.9 21.8 Portugal 40.7 33.5 21.4 Turkey 59.9 53.5 12.0 Russia, other CIS countries and Ukraine 88.7 63.4 39.8 Other
Slide 7: Geographical breakdown of pharmaceutical revenue
Geographical breakdown of pharmaceutical¹ revenue Other international revenue (2) 13.3% North Africa 2.1% Italy 15.4% Other CEE 7.1% USA 14.2% Other W. Europe 7.4% Portugal 3.0% France 9.4% Spain 7.8% Turkey 4.5% Germany 9.2% Russia, other CIS and Ukraine 6.6% Data: First nine months 2022 Pharmaceut
Slide 8: First nine months 2022 results
First nine months 2022 results (million Euro) 9M 2022 9M 2021 Change % Revenue 1,377.5 1,156.2 19.1 Gross Profit 954.7 843.2 13.2 as % of revenue 69.3 72.9 Adjusted Gross Profit(1) 990.4 843.2 17.5 as % of revenue 71.9 72.9 SG&A Expenses 411.8 347.1 18.6 as % of revenue 29.9 30.0 R&D Expenses 155.7
Slide 9: First nine months 2022 results: Operating Segments
First nine months 2022 results Operating Segments REVENUE EBITDA (1) Treatments for rare diseases 31.2% Treatments for rare diseases 36.4% Specialty and primary care 68.8% Specialty and primary care 63.6% Margin on Sales: Treatments for rare diseases: EBITDA (1) 43.7% Specialty and primary care: EBI
Slide 10: First nine months 2022 cash flow
First nine months 2022 cash flow (million Euro) 9M 2022 9M 2021 Change EBITDA (1) 516.2 447.9 68.3 Movements in working capital (40.2) 12.8 (53.0) Changes in other assets & liabilities (5.8) (14.6) 8.8 Interest received/(paid) (13.3) (11.3) (2.0) Income Tax Paid (56.0) (61.6) 5.6 Other (39.2) (5.1)
Slide 11: Net financial position
Net financial position Net debt / EBITDA at end September just below 2x 30 SEPT 2022 31 DEC 2021 Change (million Euro) Cash and cash equivalents 346.6 244.5 102.1 Short-term debts to banks and other lenders (5.7) (8.7) 3.0 Loans and leases – due within one year(1) (287.0) (221.5) (65.5) Loans and le
Slide 12: 2022 Financial projections
2022 Financial projections FY 2021 FY 2022 Actual Target Old New Key assumptions • Revenue and EBITDA(1) ahead of original target thanks to: - Strong underlying performance across both BU and key Revenue 1,580 1,720 - 1,780 +/- 1,860 growth platforms yoy growth % +9.1% +10.8% +17.7% - Marginally pos
Slide 13: Appendix
Appendix 4 & RECORDATI
Slide 14: First nine months 2022 results – Details
First nine months 2022 results – Details Reconciliation of Net income to EBITDA(1) Summary of key items (million Euro) 9M 2022 9M 2021 Change % • Sharp appreciation of RUB (and USD) results in €18.2 million unrealized FX losses and consolidation Net income 241.5 296.4 (18.5) adjustments in first nin
Slide 15: Questions & Answers
Questions & Answers NY & RECORDATI
Slide 16: Company declarations, disclaimers and profile
Company declarations, disclaimers and profile DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY’S FINANCIAL REPORTS The manager responsible for preparing the company’s financial reports Luigi La Corte declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Fina